☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Exubera unpopular in Germany

The Institute of Quality and Efficiency in Health Care (IQWiG), the German equivalent of NICE, has completed a Rapid Review of Inhaled Insulin (Exubera)®.

The report aimed to compare inhaled insulin to subcutaneous insulin over several patient-relevant endpoints including HbA1c control, quality of life, treatment satisfaction, hypoglycaemia, adverse drug events and prevention of complications.

The report concluded that:

  • the risks of hypoglycaemia may be higher
  • long term treatment risks are unclear
  • reductions in the number of injections may not improve patient satisfaction or quality of life

IQWiG recommend that additional work needs to be undertaken in these areas to allow a more conclusive evaluation to be completed.

Action: Clinicians involved in treating diabetes may wish to be aware of the latest reviews of inhaled insulin. A Technology Appraisal from NICE is due in October 2006.

Share 'Exubera unpopular in Germany' by emailShare 'Exubera unpopular in Germany' on FacebookShare 'Exubera unpopular in Germany' on TwitterShare 'Exubera unpopular in Germany' on LinkedInShare 'Exubera unpopular in Germany' on reddit


One Comment to “Exubera unpopular in Germany”

  1. Thanks for that Matthew.

    Comment by Anthony — May 23, 2006 #

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.